HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: In this regard, histone deacetylases (HDACs) represent the most widely studied therapeutic targets, with HDAC inhibitors (HDACi) including chidamide, vorinostat and romidepsin, approved for use in the therapy of cutaneous T-cell lymphoma (23, 30).